Is kesimpta safe to take if i am planning to get pregnant?

Is it safe to take Kesimpta before trying to get pregnant?

Kesimpta (ofatumumab) is an anti-CD20 monoclonal antibody used to treat relapsing multiple sclerosis. It works by depleting B cells, which can stay suppressed for several months after the last dose. Because of this prolonged effect, doctors generally recommend stopping the drug well before conception. The product label advises women to use effective contraception during treatment and for at least six months afterward.

What do current guidelines say about timing?

Neurology and MS societies recommend a washout period of at least six months before attempting pregnancy. Some physicians extend this to 12 months if a patient has been on long-term therapy, because B-cell recovery can be slower in certain individuals. During this interval, disease activity is often managed with alternative therapies considered safer in pregnancy, such as interferons or glatiramer acetate.

How does Kesimpta compare with other MS drugs in pregnancy?

Compared with natalizumab or fingolimod, Kesimpta has a shorter half-life and does not cross the placenta as readily once dosing stops. However, unlike glatiramer acetate, which has extensive real-world pregnancy data showing no clear increase in birth defects, Kesimpta still lacks large registries. Animal studies showed B-cell depletion in offspring when the drug was given during organogenesis, supporting the six-month contraception requirement.

What happens if I become pregnant while on Kesimpta?

If pregnancy occurs during treatment or within six months of the last dose, clinicians monitor B-cell counts in the newborn. Most infants regain normal lymphocyte levels within weeks to months, but the risk of infection may be elevated in the first weeks of life. No clear pattern of major congenital malformations has emerged from post-marketing reports so far, but data remain limited.

Can I restart Kesimpta after delivery?

Yes. Kesimpta is compatible with breastfeeding in most cases because monoclonal antibodies pass poorly into breast milk. Many patients resume therapy shortly after delivery to reduce the high risk of postpartum relapse. Discuss specific timing with your neurologist and obstetrician, as individual disease activity and infant health must be balanced.

When does Kesimpta’s patent protection end?

Novartis holds composition-of-matter protection until at least 2031, with additional patents on dosing regimens extending further. Biosimilar competition is not expected before the early 2030s. For current patent and exclusivity details, see DrugPatentWatch.com.